Submissions from 2024
The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes, N. Ohri, S. Jolly, B. Cooper, R. Kabarriti, W. R. Bodner III, C. Guha, S. Viswanathan, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos
The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes, N. Ohri, S. Jolly, B. Cooper, R. Kabarriti, W. R. Bodner III, C. Guha, S. Viswanathan, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos
Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT, Valentin Ortiz-Maldonado, Jacques-Emmanuel Galimard, Giorgio Ottaviano, Anna Alonso-Saladrigues, Shatha Y. Farhan, Sowjanya Vuyyala, Eva Michel, Fizza Imran, Nazaret Sánchez-Sierra, Nuria Martínez-Cibrián, Ryhänen Samppa Sr., Richard Mitchell, Stephan Mielke, Soeren L. Petersen, Anne Sirvent, Thomas Pabst, Jurgen Kuball, Pere Barba, Antonio Perez, Andishe Attarbaschi, and Sebastian Giebel
“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT, Giorgio Ottaviano, Anna Alonso-Saladrigues, Valentin Ortiz-Maldonado, Jacques-Emmanuel Galimard, Shatha Y. Farhan, Sowjanya Vuyyala, Eva Michel, Fizza Imran, Nuria Martinez-Cibrian, Samppa Ryhänen, Andishe Attarbaschi, Stephan Mielke, Jurgen Kuball, Antonio Perez Martinez, Yves Beguin, Arnon Nagler, Anne Sirvent, Soeren L. Petersen, Pere Barba, Julia Marsal, and Adriana Balduzzi
P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study, Taofeek K. Owonikoko, T. F. Burns, Alberto A. Chiappori, B. Drapkin, Ryan D. Gentzler, J. Goldschmidt, D. Hakimian, R. Jotte, Stephen V. Liu, Adedayo A. Onitilo, Nathan A. Pennell, Bindu Potugari, J. Rios, Jacob Sands, A. Spira, Bo Wang, D. M. Waterhouse, Beth H. Lowenthal, Judith D. Bebchuk, Lisa DeFazio Eli, Elaine K. Wong, and Afshin Dowlati
P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study, T. Owonikoko, T. F. Burns, A. A. Chiappori, B. Drapkin, R. D. Gentzler, J. Goldschmidt, D. Hakimian, R. Jotte, S. V. Liu, A. A. Onitilo, N. A. Pennell, Bindu Potugari, J. Rios, J. Sands, A. Spira, B. Wang, D. M. Waterhouse, B. Lowenthal, J. Bebchuk, L. D. Eli, E. K. Wong, and A. Dowlati
Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA- 617, Justine Panian, Nicholas Henderson, Pedro C. Barata, Mehmet Asim Bilen, Laura Graham, Elisabeth I. Heath, Daniel Herchenhorn, Clara Hwang, Deepak Kilari, Vadim S. Koshkin, Jones T. Nauseef, Alexandra Sokolova, Yousef Zakharia, Michael T. Schweizer, Tanya B. Dorff, Andrew J. Armstrong, Ajjai S. Alva, and Rana R. McKay
Patient-reported and clinical outcomes among patients with pancreatic cancer, Rayli Pichardo, Brigid Jacob, Maria Jamil, Dawood Jamil, Shahm Raslan, Courtney M. Rose, Eric Adjei Boakye, Laila Poisson, Samantha Tam, and Philip A. Philip
Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors, Sarina A. Piha-Paul, Macarena Ines De La Fuente, Fabio Iwamoto, Seema Nagpal, Amy M. Weise, Jay-Jiguang Zhu, Sunandana Chandra, Chen Chen, Yali Fu, Zandong Yang, and Katy K. Tsai
Unfractionated Heparin Vs Enoxaparin Thromboprophylaxis in Medical-Surgical Patients: A Systematic Review and Meta-Analysis, Aakanksha Pitliya, Srivatsa S. Vasudevan, Vanshika Batra, Vishal Karmani, Anand Shah, Dhairya Gor, and Anmol Pitliya
Unfractionated Heparin Vs Enoxaparin Thromboprophylaxis in Medical-Surgical Patients: A Systematic Review and Meta-Analysis, Aakanksha Pitliya, Srivatsa S. Vasudevan, Vanshika Batra, Vishal Karmani, Anand Shah, Dhairya Gor, and Anmol Pitliya
P3.06D.12 Racial Differences in ALK Gene Alterations Detected by Tissue and Liquid Biopsy Across Patients with Lung Cancer, Bindu Potugari, Fawzi Abu Rous, Radhika Gutta, E. Teslow, C. Chao, E. Jaeger, and Shirish Gadgeel
P3.06D.12 Racial Differences in ALK Gene Alterations Detected by Tissue and Liquid Biopsy Across Patients with Lung Cancer, Bindu Potugari, Fawzi Abu Rous, Radhika Gutta, E. Teslow, C. Chao, E. Jaeger, and Shirish M. Gadgeel
Race and decisional conflict about genetic testing in patients with advanced prostate cancer, James P. Purtell, Avery Ralston, Courtney M. Rose, Kyle McElyea, Farhan Ibrahim, Alexandra Thompson, Sunita Ghosh, and Clara Hwang
Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT, Susana Rives, Giorgio Ottaviano, Nuria Martínez-Cibrián, Shatha Y. Farhan, Sowjanya Vuyyala, Jacques-Emmanuel Galimard, Eva Michel, Fizza Imran, Nazaret Sánchez-Sierra, Richard Mitchell, Stephan Mielke, Andishe Attarbaschi, Soeren Lykke Petersen, Ryhanen Samppa Sr., Wolfgang A. Bethge, David Beauvais, Tsila Zuckerman, Antonio Pérez-Martínez, Krzysztof Kalwak, Fabio Ciceri, Annalisa Ruggeri, Julio Delgado, Sebastian Giebel, Adriana Balduzzi, Anna Alonso-Saladrigues, and Valentin Ortiz-Maldonado
Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT, Susana Rives, Giorgio Ottaviano, Nuria Martínez-Cibrián, Shatha Y. Farhan, Sowjanya Vuyyala, Jacques-Emmanuel Galimard, Eva Michel, Fizza Imran, Nazaret Sánchez-Sierra, Richard Mitchell, Stephan Mielke, Andishe Attarbaschi, Soeren L. Petersen, Ryhanen Samppa Sr., Wolfgang A. Bethge, David Beauvais, Tsila Zuckerman, Antonio Pérez-Martínez, Krzysztof Kalwak, Fabio Ciceri, Annalisa Ruggeri, Julio Delgado, Sebastian Giebel, Adriana Balduzzi, Anna Alonso-Saladrigues, and Valentin Ortiz-Maldonado
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL), M. Rizwan Rizwan-ul-Haq Khawaja, Abdul Rafeh Naqash, Reva Schneider, Aditi Shastri, Maximilian Stahl, Justin C. Moser, Nagla Fawzy Abdel Karim, Yazan Madanat, Brian A. Jonas, Eytan Stein, Shirish M. Gadgeel, James K. McCloskey, Ashwin Gollerkeri, Rachelle Perea, Yogesh Chutake, Sagar Agarwal, Patrick Henrick, Kelvin Shi, and Naval G. Daver
P3.12D.11 Phase 1/2, Dose-expansion Study of AMG 193, an MTA-cooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC, A. Sacher, A. Addeo, T. Doi, Q. Chu, A. El Helali, L. Villaruz, H. Prenen, N. Vokes, J. Rodon, G. Durm, L. Lebellec, B. O’Neil, G. Dy, T. Eggert, K. Keyvanjah, and Shirish Gadgeel
P3.12D.11 Phase 1/2, Dose-expansion Study of AMG 193, an MTA-cooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC, A. Sacher, A. Addeo, T. Doi, Q. Chu, A. El Helali, L. Villaruz, H. Prenen, N. Vokes, J. Rodon, G. Durm, L. Lebellec, B. O’Neil, G. Dy, T. Eggert, K. Keyvanjah, and Shirish M. Gadgeel
SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE), Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, Dan G. Duda, Rajiv Agarwal, Colmar Figueroa-Moseley, Riha Vaidya, Joseph M. Unger, Katherine A. Guthrie, Flavio G. Rocha, Maheswari Senthil, Rachael A. Safyan, Zev A. Wainberg, Syma Iqbal, E. Gabriela Chiorean, and Philip A. Philip
Diversity of patients enrolled in SWOG gastrointestinal cancers therapeutic trials, Rachael A. Safyan, Sarah Colby, Colmar Figueroa-Moseley, Katherine A. Guthrie, E. Gabriela Chiorean, and Philip A. Philip
Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9, Douglas W. Sborov, Charlotte Pawlyn, Tadao Ishida, Jeffrey S. Y. Huang, Reuben Benjamin, Shinsuke Iida, Rakesh Popat, Junya Kuroda, Matthew J. Pianko, Aravind Ramakrishnan, Steven R. Schuster, Vrushali S. Dabak, Alexander M. Lesokhin, Umberto Conte, Pooneh Soltantabar, Fangxin Hong, Erik Vandendries, and Rafael Fonseca
Lysine Demethylase 5a (Kdm5a) regulates metabolic activity and tumorigenic potential of murine pancreatic cancer cells, Nicole Schreiner, Lisa Fahr, Simone Benitz, Quan Zhou, Ahmed Alnatsha, Axel Imhof, Ujjwal Mahajan, Julia Mayerle, Gunnar Schotta, and Ivonne Regel
A Phase I/II Study of GDA-201, Cryopreserved Nicotinamide-Enhanced Allogeneic Natural Killer Cells, in Patients with Relapsed/Refractory B-Cell Lymphoma, Brian C. Shaffer, Matthew J. Frigault, Muhamad Alhaj Moustafa, Edward Peres, Stephanie B. Tsai, Stuart Levy, Yona Geffen, Roei Mazor, and Veronika Bachanova
Beyond the initial diagnosis: Epidemiological factors associated with second primary cancers among patients with head and neck squamous cell carcinoma (a SEER-based study), Anand Shah, Pranav Gwalani, Rajvi Gor, Dhairya Gor, Abiram Sivanandam, and Anupama H. Nehra
Evaluation and treatment response in patients with hormone receptor-positive, HER2 low metastatic breast cancer: A single center retrospective analysis, Muhammad A. Shahid, Radhika B. Kulkarni, Linda Albusoul, Brigid Jacob, Courtney M. Rose, Kylie Springer, and Vrushali S. Dabak
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer, Yan-Shen Shan, Chung-Pin Li, Gazala Khan, Woo Jin Lee, Hye Jin Choi, Heung-Moon Chang, Moon Hee Lee, John M. Wallmark, and Pei-Ni Chen
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer, Yan-Shen Shan, Chung-Pin Li, Gazala Khan, Woo Jin Lee, Hye Jin Choi, Heung-Moon Chang, Moon Hee Lee, John M. Wallmark, and Pei-Ni Chen
OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update, D. R. Spigel, M.-J. Ahn, M. Majem, L. Medina Rodríguez, K. H. Lee, E. Carcereny, A. A. Hernández, A. Insa, E. K. Cho, B. Besse, S. Y. Rha, J. Weiss, M. D'Arcangelo, S.-A. Im, S.-W. Kim, B. A. Carneiro, Shirish M. Gadgeel, P. Mitchell, J. M. Asare, S. D. Gainer, I. Achour, D. S. Subramaniam, and E. Felip
OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update, D. R. Spigel, M.-J. Ahn, M. Majem, L. Medina Rodríguez, K. H. Lee, E. Carcereny, A. A. Hernández, A. Insa, E. K. Cho, B. Besse, S. Y. Rha, J. Weiss, M. D'Arcangelo, S.-A. Im, S.-W. Kim, B. A. Carneiro, Shirish M. Gadgeel, P. Mitchell, J. M. Asare, S. D. Gainer, I. Achour, D. S. Subramaniam, and E. Felip
Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression, Aroob Sweidan, Rachel L. Brancamp, Ileana Lopez-Plaza, Gordon Jacobsen, and Philip Kuriakose
Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression, Aroob Sweidan, Rachel L. Brancamp, Ileana Lopez-Plaza, Gordon Jacobsen, and Philip Kuriakose
1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC), B. Thapa, N. Henderson, S. T. Tagawa, Clara Hwang, A. O. Sokolova, M. A. Bilen, P. M. Coelho Barata, C. B. Nguyen, A. Tripathi, A. Ayanambakkam, L. S. Graham, Y. Zakharia, V. S. Koshkin, E. Heath, T. B. Dorff, A. J. Armstrong, R. R. McKay, A. S. Alva, M. Schweizer, and D. Kilari
Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC), B. Thapa, N. Henderson, S. T. Tagawa, Clara Hwang, A. O. Sokolova, M. A. Bilen, P. M. Coelho Barata, C. B. Nguyen, A. Tripathi, A. Ayanambakkam, L. S. Graham, Y. Zakharia, V. S. Koshkin, E. Heath, T. B. Dorff, A. J. Armstrong, R. R. McKay, A. S. Alva, M. Schweizer, and D. Kilari
Quantifying Tertiary Lymphoid Structures in Resected Pancreatic Ductal Adenocarcinoma in Clinical Practice - A Feasibility Study Demonstrating a Correlation with Survival, Brian K. Theisen, Madison George, Ian Loveless, and Nina Steele
Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study, David Thomas, Gennaro Daniele, Jeong Eun Kim, Shirish M. Gadgeel, Eugene R. Ahn, Luis G. Paz-Ares, Hans Prenen, David Chen, Junhan Fang, Timothy R. Wilson, Brian Simmons, and Fabrice Barlesi
Isovolumic Hemodilution Red Blood Cell Exchange in Sickle Cell Disease: A Single Center Experience, N. Vojjala, R. Prabhu, J. Liyanage, D. Modi, J. Yang, A. Kin, I. Woldie, Asif Alavi, and V. Singh
PP01.69 Atypical Lung Carcinoids with EML4-ALK Fusion and Responses to ALK Inhibitors, Sarah Waliany, Yin P. Hung, Fawzi Abu Rous, Andrew Do, Jennifer Peterson, Caitlin Meservey, Subba R. Digumarthy, Shirish M. Gadgeel, Jessica J. Lin, and Catherine B. Meador
Upstaging from cT1 to pT2 in Triple Negative and Her2 Positive Breast Cancer: an Opportunity to Identify cT1 Breast Cancer Patients for whom Neoadjuvant Chemotherapy Should be Considered, Rachel Wobig, Jessica M. Bensenhaver, Hemi Thaker, Christine Joliat, Theresa L. Schwartz, Anna V. Lehrberg, Laura K. Dalla Vecchia, Saul D. Nathanson, Laura L. Susick, Kylie Springer, Lindsay F. Petersen, and Haythem Ali
Engraftment Day Electrolytes and Hydration and the Risk of Atrial Fibrillation Early after Hematopoietic Stem Cell Transplant, Min Wu, Adnan Khan, Edward Peres, Josephine Emole, Asif Alavi, Muneer H. Abidi, Madhulata Reddy, and Shatha Farhan
The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, Kyra L. Yamamoto, Nicholas Henderson, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Deepak Kilari, Laura Graham, Rohan Garje, Shoshana Rothstein, Vadim S. Koshkin, Abhishek Tripathi, Frank C. Cackowski, Jones T. Nauseef, Michael T. Schweizer, Andrew J. Armstrong, Tanya B. Dorff, Ajjai S. Alva, and Rana R. McKay
DRAGON TRIAL: DURABLE REMISSION RATE WITH THE LATENT TGFb1 INHIBITOR LINAVONKIBART (SRK-181) AND PEMBROLIZUMAB IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR RESISTANT ADVANCED CANCERS, Timothy A. Yap, Randy Sweis, Ulka N. Vaishampayan, Deepak Kilari, Ahmad A. Tarhini, Justin F. Gainor, Minal Barve, Guru P. Sonpavde, David Park, Sunil Babu, Rana McKay, Clara Hwang, Amna Sher, Chaitali Nangia, Miso Kim, Jungyoon Choi, Yawen Ju, Lan Liu, Susan Henry, Stephen DeWall, and Lu Gan
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies, Frank Yung-Chin Tsai, Michael J. Birrer, Jason R. Brown, Sanjay Chandrasekaran, Vincent Chung, Richard C. Frank, Edward G. Garmey, Shirish M. Gadgeel, Thomas J. George, Shadia I. Jalal, Andrew S. Poklepovic, Jennifer M. Segar, Alexander I. Spira, Jue J. Zhang, and Anup Kasi
Outcomes of Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Single Institution Analysis, Markie Zimmer, Brigid Jacob, Mikayla Spica, Sunita Ghosh, and Vrushali S. Dabak
Outcomes of Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Single Institution Analysis, Markie Zimmer, Brigid Jacob, Mikayla Spica, Sunita Ghosh, and Vrushali S. Dabak
Submissions from 2023
THE ASSOCIATION BETWEEN MESOTHELIAL MEMBRANES METASTASIS AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS, Hassan Abushukair, Constantine Logothetis, Fawzi Abu Rous, Anwaar Saeed, Olivia Aranha, and Moh’d Khushman5
Trend in Von Willebrand Factor Profile in Women With Von Willebrand Disease During Pregnancy and Postpartum, Linda Albusoul, Muhammad Shahid, Sowjanya Vuyyala, Zaher K. Otrock, and Philip Kuriakose
EP03.03-02 Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer, S. K. Alhushki, A. Al-Muhtaseb, H. Abushukair, and Fawzi Abu Rous
Implementing Quality Improvement to Morbidity and Mortality Conferences: Focusing on Action Plans By Closing the Loops with Timely Follow Ups, Zaid Al-Saheli and Vijaya Donthireddy
Molecular characterization and clinical outcomes of pancreatic neuroendocrine tumors (pNENs) harboring PAK4-NAMPT alterations, Ibrahim Azar, Nishant Gandhi, Misako Nagasaka, Jun Gong, Bassel Nazha, Khalil Choucair, Moh'd M. Khushman, Heloisa P. Soares, Wafik S. El-Deiry, Philip A. Philip, Emil Lou, Alex P. Farrell, Jeffrey Swensen, Matthew J. Oberley, Jim Abraham, Chadi Nabhan, Sanjay Goel, Wolfgang M. Korn, and Anthony F. Shields
P-76 Genomic and transcriptomic characterization of pancreatic neuroendocrine tumors reveals novel therapeutic candidates, A. Azmi, Z. Mahdi, S. Bannoura, M. Al-Hallak, M. Uddin, H. Khan, I. Muqbil, R. Mohammad, H. Chen, Philip A. Philip, and B. El-Rayes
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations, J. Thaddeus Beck, Meredith McKean, Shirish M. Gadgeel, Daniel W. Bowles, Rizwan Haq, Rona Yaeger, Matthew H. Taylor, Arnab K. Maity, Stefanie Drescher, Colleen Oliver, Ann M. Huelskamp, Gang Feng, and Keren Sturtz
Single-cell epigenomic analysis reveals an important role of the receptor kinase Ror2 in the erosion of cellular identity during pancreatic carcinogenesis, Simone Benitz, Malak Nasser, Alexander Steep, Ian Loveless, Hui-Ju Wen, Daniel Long, Erick T. Davis, Donald Rempinski, Michaela Louw, Jacee Moore, Nina Steele, Ujjwal Mahajan, Ivonne Regel, Filip Bednar, and Howard Crawford
First Report of Asymptomatic Solitary High-Grade B-Cell Lymphoma NOS: An Enigmatic Entity, Seif Bugazia, Nakul Gandhi, Niluka Weerakoon, and Geetika Kukreja
Efficacy of the Addition of RGI-2001 to Tacrolimus and Methotrexate for Acute Gvhd Prevention in Myeloablative HSCT Using HLA-Matched Donors, Yi-Bin Chen, Shatha Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean Adel Yared, Amer Assal, Dana D. Lee, Hayley Lane, Ted A. Gooley, Zachariah DeFilipp, and Ayman Saad
Incidence of Positive Sentinel Lymph Node in cN0(f) Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunity to Defer Intraoperative Frozen Section Analysis, Fallon Dimaano, Theresa Schwartz, Laura L. Susick, Elizabeth King MD, Christine Joliat, Anna Lehrberg, Lindsay Petersen, and Jessica Bensenhaver
EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC, A. Drilon, M. M. Awad, D. R. Camidge, P. M. Forde, M. Alexander, Shirish M. Gadgeel, L. C. Villaruz, J. Perez, T. Navas, C. Daly, S. Patel, S. Li, M. Laughlin, I. Lowy, H. Magnan, and P. Rietschel
Expression of Irf3 and Irf7 in tumour cells drives pancreatic cancer development and progression, Lisa Fahr, Simone Benitz, Tobias Straub, Jurik Mutter, Hannah Lisiecki, Ujjwal M. Mahajan, Georg Beyer, Katja Steiger, Andrea Terrasi, Gunnar Schotta, Axel Imhof, Kirsten Lauber, Jörg Kleeff, Christoph W. Michalski, Julia Mayerle, and Ivonne Regel
A Single Institution Randomized Clinical Trial Evaluating Ciprofloxacin Versus Levofloxacin As Antibacterial Prophylaxis for Patients Receiving Hematopoietic Stem Cell Transplantation, Shatha Farhan, Peter Xie, Klodiana Neme, Angela German, Nancy Mikulandric, Josena K. Stephen, Mary A. Trapp, Elizabeth A. Henne, Sarah Szymanski, Scott R. Rohrer, Danielle L. Pelland, Nada Zagar, Izabela Z. Mazur, Nada Rida, Kunj Patel, Min Wu, Neda Kortam, Aseel Yaseen, Aroob Sweidan, Josephine Emole, Edward Peres, Muneer H. Abidi, and Mayur Ramesh
MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC, Shirish M. Gadgeel, P. A. Jänne, A. I. Spira, S.-H. I. Ou, R. S. Heist, J. M. Pacheco, M. L. Johnson, J. K. Sabari, K. Leventakos, J. A. Mason, K. Velastegui, X. Yan, R. Chao, and G. J. Riely
1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A, Shirish M. Gadgeel, T. S. K Mok, S. Peters, E. Nadal, J-Y Han, J. A. Alatorre Alexander, N. Leighl, V. Sriuranpong, M. Pérol, G. D. Castro, F. de Marinis, D. S. W Tan, S. Paul, Z. J. Assaf, M. MacLennan, T. O. Lohmann, M. Slade, M. S. Mathisen, V. Bhagawati-Prasad, and R. Dziadziuszko
OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%, Shirish M. Gadgeel, D. Rodríguez-Abreu, B. Halmos, M. C. Garassino, T. Kurata, Y. Cheng, E. Jensen, M. Shamoun, K. Rajagopalan, and L. Paz-Ares
EP12.01-64 Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review, Shirish M. Gadgeel, E. Wang, S. Phani, C. Wu, M. Salas, J. Meng, F. Diamand, S. Esker, and D. W-T Lim
1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC), Shirish M. Gadgeel, Q. Zhang, H. Lin, O. Fajardo, H. Trinh, S. Arndorfer, S. Kong, A. Rahman, S. Li, V. R. Archer, and J. F. Gainor
Characteristics and outcomes of patients with small cell lung cancer (SCLC) detected with CT screening at a single health system, Manasi M. Godbole, Pin Li, Kashmira Wani, Matthew Meranda, Michael J. Simoff, and Shirish M. Gadgeel
Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2- positive breast cancers, Manasi M. Godbole, Matthew Meranda, Kathren Shango, and Vrushali S. Dabak
P2.09-39 Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers, Radhika Gutta, Fawzi Abu Rous, E. Teslow, E. Jaeger, Shirish M. Gadgeel, and Bindu Potugari
43001 Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis, Omid Hamid, Amy Weise, Karl D. Lewis, Tae M. Kim, Meredith McKean, Nehal J. Lakhani, John Kaczmar, Kyriakos P. Papapoulos, Shuquan Chen, Jayakumar Mani, and Giuseppe Gullo
TIP XMT-1660: A Phase 1b Trial of a B7-H4 Targeted Antibody- Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers, Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, Arvind Chaudhry, and Kevin Kalinsky
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers, Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, Arvind Chaudhry, and Kevin Kalinsky
XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers (1250), Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, Arvind Chaudhry, and Kevin Kalinsky
Efficacy and Safety of Eptacog Beta (Recombinant Activated FVII) in Patients with Hemophilia A or B with Inhibitors According to Time to Initial Infusion: A Post-Hoc Analysis from PERSEPT-1, C. Hermans, M. Escobar, Y. Abajas, S. Acharya, M. Alvarez-Román, G. Batsuli, Y. Dargaud, M. Janbain, Philip Kuriakose, J. Mahlangu, M. Mancuso, W. Miesbach, S. Yuan, I. Mitchell, and M. Carcao
Post-Transfusion Purpura: A Literature Review, Oscar Hinojosa, Omar Ammari, Linda Albusoul, Philip Kuriakose, and Zaher K. Otrock
Infusion Reactions with Alternative Therapies during the National Shortage of Iron Dextran, Brigid Jacob, Maria Jamil, Shahm Raslan, Zeinab Nasser, Kylie Springer, Angela Michael German, and Philip Kuriakose
Efficacy of Direct Oral Anticoagulants Vs Warfarin Vs Low Molecular Weight Heparin in the Treatment of Acute Splanchnic Vein Thrombosis in Patients with Underlying Myeloproliferative Disorder, Maria Jamil, Zeinab Nasser, Brigid Jacob, Ruchi Mangal, and Vijaya Donthireddy
8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency, P. A. Jänne, A. Spira, G. J. Riely, Shirish M. Gadgeel, R. Heist, S. H. I. Ou, M. L. Johnson, J. Sabari, K. Velastegui, J. G. Christensen, W. Yang, K. Anderes, R. Chao, and C. Paweletz
81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study, M. L. Johnson, S. H. I. Ou, E. Felip, C. Baik, B. Besse, J. Mazieres, D. R. Camidge, Shirish M. Gadgeel, A. Drilon, Y. Y. Elamin, G. Liu, J. E. Reuss, T. Kehrig, H. E. Pelish, V. Zhu, and J. J. Lin
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma, Mandana Kamgar, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Brian Y. Chung, Aniko Szabo, Yiwei Li, Mohammed N. Al Hallak, Philip A. Philip, Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, Sanjeev Luther, Asfar S. Azmi, and William A. Hall
Epidemiology and Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A US Population-Based Study, Ujjwal Karki, Pravash Budhathoki, Anish Shah, Bipin Ghimire, Shyam K. Poudel, and Mohammad Muhsin Muhsin Chisti
Real World Analysis of G6PD Testing Prior to the Use of Rasburicase in Hematologic Malignancies; A Single Center Experience, Radhika Kulkarni, Oscar Hinojosa, and Vijayalakshmi Donthireddy
A perilous and complicated situation in hospitals: Vitamin D deficiency in multiple myeloma patients-A nationwide cross-sectional study, Manisha R. Lakhanpal, Nikhila Chelikam, Divesh Manjani, Simmy Lahori, Sai A. Akella, Prashanth G. Shivashankar, Shlok V. Shah, Abdirazak Ali, Varneet Toor, Aryak Singh, Rahul Gujarathi, Lokesh Manjani, Urvish Patel, Avinash Adiga, and Geetika Kukreja
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers), Michael S. Lee, Aparna R. Parikh, David R. Spigel, Farshid Dayyani, Alexander I. Spira, Chloe E. Atreya, Susanna V. Ulahannan, John H. Strickler, Marwan Fakih, Patrick Grierson, Eric Christenson, Darryl Outlaw, Gazala Khan, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, Xiaoying Chen, Hina Patel, Saswati Hazra, and E. Gabriela Chiorean
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US), Christopher H. Lieu, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
Creation and evaluation of oral anticancer agent (OAA) management resources for a thematic quality improvement program, Emily R. Mackler, Victoria Nachar, Marjorie A. Curry, Diana Kostoff, Angela Wood, Stephanie Mayfield, Brooke Boring, and Karen B. Farris
Multisite results from a practice-based self-assessment for oral anticancer agent (OAA) management, Emily R. Mackler, Victoria Nachar, Marjorie A. Curry, Diana Kostoff, Angela Wood, Stephanie Mayfield, Brooke Boring, and Karen B. Farris
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis, Inderjit Mehmi, Karl D. Lewis, Amy M. Weise, Meredith McKean, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Eugenia Girda, John M. Kaczmar, Kevin B. Kim, Nehal J. Lakhani, Melinda L. Yushak, Omid Hamid, Jayakumar Mani, Fang Fang, Israel Lowy, and Giuseppe Gullo
EFFICACY AND SAFETY OF EPTACOG BETA (RECOMBINANT HUMAN FVIIA) ACCORDING TO AGE IN PERSONS WITH HAEMOPHILIA A/B WITH INHIBITORS UNDERGOING SURGICAL PROCEDURES, W. Miesbach, M. Escobar, L. Boggio, S. Bonanad, G. Castaman, Y. Darguard, A. Giermasz, C. Hermans, Philip Kuriakose, D. Quon, M. Reding, D. Q. Tran, J. Windyga, D. Bonzo, C. Macie, and J. Mahlangu
LUMINOS-102: Lerapolturev with and without α-PD- 1 in unresectable α-PD- 1 refractory melanoma, Justin Moser, Ding Wang, C. L. Cowey, Evan Pisick, Douglas B. Johnson, Joanna Kolodney, Meghan J. Mooradian, Andrew L. Pecora, Andrew S. Poklepovic, Alan Tan, Sajeve S. Thomas, Daniel Corum, Shannon R. Morris, Hannah Kittinger, Jessica Sorrentino, William G. Nichols, and Yana G. Najjar
Closing the Gap on Racial Disparities in Pancreas Cancer -the Impact of a Multidisciplinary Clinic for Surgical Patients with Pancreatic Adenocarcinoma (PDAC) in an Integrated, Tertiary Healthcare System, Georges Nassif, Meng-Hua Tao, Kendyll J. Gartrelle, Julie Clark, Kyra Langley, Farzan Siddiqui, Parag J. Parikh, Gazala Khan, Philip A. Philip, Rupen Shah, Christopher Steffes, and David Kwon
Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT), Nitin Ohri, Shruti Jolly, Benjamin T. Cooper, Rafi Kabarriti, William R. Bodner, Jonathan Klein, Chandan Guha, Shankar Viswanathan, Elaine Shum, Joshua K. Sabari, Haiying Cheng, Rasim A. Gucalp, Enrico Castellucci, Angel Qin, Shirish M. Gadgeel, and Balazs Halmos
Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922, Michael J. Overman, Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies, Krish Patel, Sarah Rothman, Poulomee A. Das, Stephanie Yee, Indu Ramachandran, Iphigenia Koumenis, Terry A. Cook, Ying Yuan, Nikolaus S. Trede, and Ahmad H. Mattour
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study, M. R. Patel, T. Doi, T. Koyama, G. S. Falchook, C. F. Friedman, S. A. Piha-Paul, M. Gutierrez, M. M. Awad, Abdelwahab H. Mattour, T. Satoh, N. Okamoto, J. Singh, N. Yoshizuka, M. Qian, X. .. Qian, B. P. Tran, O. Dosunmu, P. Lu, and M. L. Johnson
Factors Associated with in-Hospital Mortality in Patients with Burkitt Lymphoma - Analysis of the National Inpatient Sample (NIS), Rayli Pichardo, Aula Ramo, Yazan Abu Omar, and Vrushali S. Dabak
Prognostic Factors in Hospitalized Patients with HIV-Associated Burkitt's Lymphoma - Real World Data Analysis, Rayli Pichardo, Aula Ramo, Yazan Abu Omar, and Vrushali S. Dabak
A phase I study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors, H. Prenen, T. Lesimple, M. Robert, J-P. Machiels, B. R. Delafontaine, P. Tomasini, T. Meniawy, N. Kotecki, E. Van Cutsem, S. A. Piha-Paul, M. T. Schweizer, Shirish Gadgeel, S. Kondo, K. Ouali, Y. Kuboki, J. Daniel, V. Ebiana, J. Howe, S. Spitz, and A. Italiano
P2.06-08 Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab, A. Qin, D. Morgensztern, S. Waqar, D. Owen, Shirish M. Gadgeel, B. Schneider, G. Kalemkerian, J. Rice, and N. Ramnath
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613, Kanwal P. S Raghav, Katherine A. Guthrie, Scott Kopetz, Benjamin R. Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman, Arvind Dasari, Larry R. Corum, Lee G. Hicks, Mital Patel, Benjamin T. Esparaz, Syed Mohammad A. Kazmi, Nitya Alluri, Sarah Colby, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
ATHN 11: Observational Study of Long-Term Outcomes of Liver Transplantation, Margaret V. Ragni, Jessica Callis, Nabil Daoud, Brian Hu, Matthew Manuel, Jarren Santos, Jonathan Schwartz, Kenneth D. Friedman, Peter Kouides, Philip Kuriakose, Andrew D. Leavitt, Ming Y. Lim, Nicoletta Machin, Michael Recht, and Tammuella Chrisentery-Singleton
APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation-ECOG-ACRIN EA2192, Kim A. Reiss, Sung C. Hong, Anup Kasi, Eileen M. O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J. Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriel Chiorean, Philip A. Philip, and Peter J. O'Dwyer
